Experience Ibogaine Treatment Center

Playas de Tijuana, Mexico

Experience Ibogaine Treatment Center is a long-running ibogaine clinic located in the Playas de Tijuana neighborhood, situated close to the US–Mexico border. Its proximity to San Diego makes it one of the more frequently referenced options among US-based patients exploring ibogaine-assisted treatment for substance use disorders. The clinic reports operating with licensed medical staff available around the clock and conducts a comprehensive pre-treatment medical evaluation for each incoming patient.

Conditions Listed as Treated

  • Opioid addiction (including heroin and fentanyl)
  • Methamphetamine addiction
  • Cocaine addiction
  • Alcohol addiction
  • PTSD
  • Depression
  • Traumatic brain injury (TBI)

What to Expect

The clinic states that cardiac screening is part of its intake process — an important consideration given ibogaine's known effects on cardiac rhythm, including QT interval prolongation. Patients are evaluated prior to treatment to determine medical suitability. The clinic explicitly states a full refund policy for patients who are screened and deemed unsuitable candidates, which is a notable stated policy compared to many facilities in this category.

Pricing is not published and must be requested directly from the clinic. No third-party accreditation is listed for this facility.

Before You Commit — Research Checklist

  1. Request documentation of medical staff credentials and licensing.
  2. Ask for specifics on the cardiac screening protocol (e.g., ECG requirements, QTc thresholds for disqualification).
  3. Confirm the refund policy terms in writing before making any payment.
  4. Ask what aftercare or follow-up support is provided post-treatment.
  5. Consult your own physician about ibogaine's risks, particularly if you have any cardiovascular history.
  6. Verify current legal and safety conditions for travel to Tijuana at the time of your visit.
Note on ibogaine generally: Ibogaine is not approved by the FDA and carries documented risks including cardiac events. Deaths have been reported in association with ibogaine treatment. Medical screening does not eliminate risk.